HSTO
Price:
$0.21
Market Cap:
$897.07K
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen In...[Read more]
Industry
Biotechnology
IPO Date
2013-07-25
Stock Exchange
NASDAQ
Ticker
HSTO
According to Histogen Inc.’s latest financial reports and current stock price. The company's current ROE is -80.73%. This represents a change of 123.13% compared to the average of -36.18% of the last 4 quarters.
The mean historical ROE of Histogen Inc. over the last ten years is -88.63%. The current -80.73% ROE has changed -8.91% with respect to the historical average. Over the past ten years (40 quarters), HSTO's ROE was at its highest in in the December 2019 quarter at 6.23%. The ROE was at its lowest in in the June 2020 quarter at -110.14%.
Average
-88.63%
Median
-67.59%
Minimum
-327.91%
Maximum
13.21%
Discovering the peaks and valleys of Histogen Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 128.58%
Maximum Annual ROE = 13.21%
Minimum Annual Increase = -2581.71%
Minimum Annual ROE = -327.91%
Year | ROE | Change |
---|---|---|
2022 | -72.76% | 7.04% |
2021 | -67.97% | -79.27% |
2020 | -327.91% | -2581.71% |
2019 | 13.21% | -120.10% |
2018 | -65.73% | 5.78% |
2017 | -62.14% | -54.47% |
2016 | -136.46% | 95.19% |
2015 | -69.91% | 4.04% |
2014 | -67.20% | 128.58% |
The current ROE of Histogen Inc. (HSTO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-156.22%
5-year avg
-104.23%
10-year avg
-88.63%
Histogen Inc.’s ROE is greater than Virax Biolabs Group Limited (-115.10%), less than Baudax Bio, Inc. (54.54%), greater than YS Biopharma Co., Ltd. (-50.46%), greater than NexImmune, Inc. (-59932.89%), less than Altamira Therapeutics Ltd. (783.37%), greater than Aileron Therapeutics, Inc. (-47.94%), greater than Artelo Biosciences, Inc. (-26.25%), greater than Curis, Inc. (-328.39%), greater than Timber Pharmaceuticals, Inc. (-520.78%), greater than SAB Biotherapeutics, Inc. (-94.04%), greater than Senti Biosciences, Inc. (-91.09%), less than Cingulate Inc. (11.47%), less than Bellicum Pharmaceuticals, Inc. (153.34%), greater than Hillstream BioPharma, Inc. (-47249.59%), greater than TRACON Pharmaceuticals, Inc. (-237.65%), greater than Entera Bio Ltd. (-100.37%), greater than Tempest Therapeutics, Inc. (-201.10%), less than Better Therapeutics, Inc. (129.80%), greater than Sonnet BioTherapeutics Holdings, Inc. (-398.33%), greater than Palisade Bio, Inc. (-124.86%), greater than Bright Minds Biosciences Inc. (-58.27%), greater than Tonix Pharmaceuticals Holding Corp. (-158.27%),
Company | ROE | Market cap |
---|---|---|
-115.10% | $8.81M | |
54.54% | $8.13M | |
-50.46% | $192.09M | |
-59932.89% | $304.04K | |
783.37% | $1.96M | |
-47.94% | $86.66M | |
-26.25% | $3.68M | |
-328.39% | $25.38M | |
-520.78% | $1.18M | |
-94.04% | $28.74M | |
-91.09% | $10.39M | |
11.47% | $11.75M | |
153.34% | $778.33K | |
-47249.59% | $4.17M | |
-237.65% | $136.30K | |
-100.37% | $65.20M | |
-201.10% | $25.34M | |
129.80% | $5.45K | |
-398.33% | $2.87M | |
-124.86% | $3.68M | |
-58.27% | $224.49M | |
-158.27% | $19.22M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Histogen Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Histogen Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Histogen Inc.'s ROE?
How is the ROE calculated for Histogen Inc. (HSTO)?
What is the highest ROE for Histogen Inc. (HSTO)?
What is the 3-year average ROE for Histogen Inc. (HSTO)?
What is the 5-year average ROE for Histogen Inc. (HSTO)?
How does the current ROE for Histogen Inc. (HSTO) compare to its historical average?